STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes

Journal of Cell Science

Volumn 121, Issue 3, 2008, Pages 272-281

  Krejci, Pavel ^a,b   Salazar, Lisa ^c   Goodridge, Helen S ^d   Kashiwada, Tamara A ^c   Schibler, Matthew J ^e   Jelinkova, Petra ^a   Thompson, Leslie Michels ^c   Wilcox, William R ^d,e  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cartilage; Chondrocyte; FGFR3; Fibroblast growth factor; Growth arrest; STAT

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; BONE DYSPLASIA; CARTILAGE CELL; CELL CULTURE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; GROWTH DISORDER; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; CHONDROCYTES; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-6; LUMINESCENT PROTEINS; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 40549114946     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.017160     Document Type: Article

References (44)

1. Aikawa, T., Segre, G. V. and Lee, K. (2001). Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J. Biol. Chem. 276, 29347-29352.
2. Ben-Zvi, T., Yayon, A., Gertler, A. and Monsonego-Ornan, E. (2006). Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J. Cell Sci. 119, 380-387.
3. Besser, D., Bromberg, J. F., Darnell, J. E., Jr and Hanafusa, H. (1999). A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol. 19, 1401-1409.
4. Bonofiglio, D., Gabriele, S., Aquila, S., Catalano, S., Gentile, M., Middea, E., Giordano, F. and Ando, S. (2005). Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer. Clin. Cancer. Res. 11, 6139-6147.
5. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D. and Darnell, J. E. (1996). Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93, 7673-7678.
6. Cao, X., Tay, A., Guy, G. R. and Tan, Y. H. (1996). Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16, 1595-1603.
7. Chen, L., Adar, R., Yang, X., Monsonego, E. O., Li, C., Hauschka, P. V., Yayon, A. and Deng, C. (1999). Gly369cys mutation to mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 104, 1517-1525.
8. 1/Cip1 mediated by STAT1. Science 272, 719-722.
9. Dailey, L., Laplantine, E., Priore, R. and Basilico, C. (2003). A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J. Cell Biol. 161, 1053-1066.
10. Decker, T. and Kovarik, P. (2000). Scrine phosphorylation of Stats. Oncogene 19, 2628-2637.
11. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921.
12. Deo, D. D., Axelrad, T. W., Robert, E. G., Marcheselli, V., Bazan, N. G. and Hunt, J. D. (2002). Phosphorylation of Stat-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 277, 21237-21245.
13. Durbin, J. E., Hackenmiller, R., Simon, M. C. and Levy, D. E. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443-450.
14. Henderson, J. E., Naski, M. C., Aarts, M. M., Wang, D., Cheng, L., Goltzman, D. and Ornitz, D. M. (2000). Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. J. Bone Miner. Res. 15, 155-165.
15. Herrmann, A., Sommer, U., Pranada, A. L., Giese, B., Haan, S., Becker, W., Heinrich, P. C. and Müller-Newen, G. (2003). Stat3 is enriched in nuclear bodies. J. Cell Sci. 116, 339-349.
16. Khan, K. D., Shuai, K., Lindwall, G., Maher, S. E., Darnell, J. E., Jr and Bothwell, A. L. (1993). Induction of the Ly-6A/E gene by interferon alpha/beta and gamma requires a DNA element to which a tyrosine-phosphorylated 91-kDa protein binds. Proc. Natl. Acad. Sci. USA 90, 6806-6810.
17. Kim, H. and Baumann, H. (1997). The carboxyl-terminal region of STAT3 controls gene induction by the mouse haptoglobin promoter. J. Biol. Chem. 272, 14571-14579.
18. Kisseleva, T., Bhattacharya, S., Braunstein, J. and Schindler, C. W. (2002). Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24.
19. Klint, P., Kanda, S., Kloog, Y. and Claesson-Welsh, L. (1999). Contribution of Stc and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 18, 3354-3364.
20. Köstner, M. and Hauser, H. (1999). Dynamic redistribution of Statl protein in IFN signaling visualized by GFP fusion proteins. Eur. J. Biochem. 260, 137-144.
21. Krejci, P., Bryja, V., Pachernik, J., Hampl, A., Pogue, R., Mekikian, P. and Wilcox, W. R. (2004). FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp. Cell Res. 297, 152-164.
22. Krejci, P., Masri, B., Fontaine, V., Mekikian, P. B., Weis, M., Prats, H. and Wilcox, W. R. (2005). Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. Cell Sci. 118, 5089-5100.
23. Krejci, P., Masri, B., Salazar, L., Farrington-Rock, C., Prats, H., Michels Thompson, L. and Wilcox, W. R. (2007). Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J. Biol. Chem. 282, 2929-2936.
24. Legeai-Mallet, L., Benoist-Lasselin, C., Delezoide, A., Munnich, A. and Bonaventure, J. (1998). Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J. Biol. Chem. 273, 13007-13014.
25. CiP1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 34, 26-36.
26. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X. and Deng, C. (1999). A lys644glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8, 35-41.
27. Liddle, F. J., Alvarez, J. V., Poli, V. and Frank, D. A. (2006). Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active Stat mutants. Biochemistry 45, 5599-5605.
28. Lievens, P. M,-J. and Liboi, E. (2003). The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J. Biol. Chem. 278, 17344-17349.
29. Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and De Crombrugghe, B. (2004). Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 18, 290-305.
30. Nowroozi, N., Raffioni, S., Wang, T., Apostol, B. L., Bradshaw, R. A. and Michels Thompson, L. (2005). Sustained Erk1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum. Mol. Genet. 14, 1529-1538.
31. Passos-Bueno, M. R., Wilcox, W. R., Jabs, E. W., Sertie, A. L., Alonso, L. G. and Kitoh, H. (1999). Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 14, 115-125.
32. Priore, R., Dailey, L. and Basilico, C. (2006). Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J. Cell. Physiol. 207, 800-808.
33. Raffioni, S., Zhu, Y. Z., Bradshaw, R. A. and Thompson, L. M. (1998). Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. J. Biol. Chem. 273, 35250-35259.
34. Raucci, A., Laplantine, E., Mansukhani, A. and Basilico, C. (2004). Activation of the Erk1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem. 279, 1747-1756.
35. Reich, N. C. and Liu, L. (2006). Tracking STAT nuclear traffic. Nat. Rev. Immunol. 6, 602-612.
36. Rozenblatt-Rosen, O., Mosonego-Ornan, E., Sadot, E., Madar-Shapiro, L., Sheinin, Y., Ginsberg, D. and Yayon, A. (2002). Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations, J. Cell Sci. 115, 553-562.
37. Sahni, M., Ambrosetti, D., Mansukhani, A., Gertner, R., Levy, D. and Basilico, C. (1999). FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13, 1361-1366.
38. Sahni, M., Raz, R., Coffin, J. D., Levy, D. and Basilico, C. (2001). Stat1 mediates the increased apoptosis and reduced chondracyte proliferation in mice overexpressing FGF2. Development 128, 2119-2129.
39. Shi, C.-S. and Kehrl, J. H. (2004). Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J. Biol. Chem. 279, 17224-17231.
40. Sims, N. A., Jenkins, B. J., Quinn, J. M., Nakamura, A., Glatt, M., Gillespie, M. T., Ernst, M. and Martin, T. J. (2004). Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J. Clin. Invest. 113, 379-389.
41. Sironi, J. J. and Ouchi, T. (2004). Stat1 -induced apoptosisis mediated by caspases 2, 3, and 7. J. Biol. Chem. 279, 4066-4074.
42. Su, S. W., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W. A. and Fu, X. (1997). Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288-292.
43. Wen, Z., Zhong, Z. and Darnell, J. E., Jr (1995). Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-250.
44. Yamanaka, Y., Tanaka, H., Koike, M., Nishimura, R. and Seino, Y. (2003). PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J. Bone Miner. Res. 18, 1395-1403.